Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Crutial 450 day data.

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Nov 14, 2022 8:04am

317 Views

Post# 35095986

RE:Crutial 450 day data.

Wildbird1 ... Nice post. Thanks for adding your vision.

And thanks for this refresher:

All the above could explain why Dr.Arkady Mandel, in a June 24,2022 PressRelease said " The success in the Phase 1b NMIBC clinical study, has led to the impressive preliminary results demonstrated in the Phase II NMIBC clinical study".

Note: Dr.Mandel gave us a big clue when he said " has led to" indicating that these impressive preliminary results are genuine, and only need to be compiled and certified in Dec 22.